Rezdiffra (Resmetirom) East Asian Documented Efficacy Gaps

What Is Resmetirom and Why Does Ethnicity Matter?

Resmetirom is a liver-directed thyroid hormone receptor beta (THR-beta) selective agonist approved by the FDA in March 2024 for adults with MASH and moderate-to-advanced hepatic fibrosis (F2-F3) [1]. The drug reduces hepatic fat by mimicking thyroid hormone signaling in liver tissue while minimizing systemic thyroid effects. Ethnicity matters here for two distinct reasons: pharmacogenomics and disease phenotype.

The Pharmacogenomic Angle

Resmetirom is metabolized primarily by CYP2C8, with secondary contributions from CYP2C19 and CYP2D6 [2]. East Asian populations carry loss-of-function CYP2C19 alleles (particularly CYP2C19*2 and CYP2C19*3) at frequencies of roughly 13-23%, compared with 2-5% in European-ancestry populations [3]. Poor metabolizers at CYP2C19 may experience higher plasma drug exposure, which could shift the benefit-risk balance. The FDA label for resmetirom does not yet include dose adjustments specific to CYP2C19 genotype, but the PharmGKB database classifies CYP2C19 polymorphisms as clinically actionable for several hepatically metabolized drugs in the same metabolic pathway [4].

The Disease-Phenotype Angle

East Asian patients develop MASH and significant hepatic fibrosis at lower BMI values than Western patients [5]. The WHO Asia-Pacific criteria define overweight as BMI ≥23 kg/m², a threshold roughly 2 units lower than the conventional Western cutoff [6]. This matters for resmetirom because the approved dosing algorithm uses BMI <35 kg/m² for 80 mg and BMI ≥35 kg/m² for 100 mg. An East Asian patient with severe MASH and BMI of 26 kg/m² would receive 80 mg under current labeling, even though their metabolic risk profile may differ substantially from a Western patient at the same BMI.

MAESTRO-NASH Trial: What the Data Actually Show

MAESTRO-NASH was the key phase 3 randomized controlled trial that supported FDA approval of resmetirom. Published in the New England Journal of Medicine in 2024, the trial enrolled 966 patients across three arms: resmetirom 80 mg, resmetirom 100 mg, and placebo [1].

Primary Efficacy Results

At 52 weeks, 26.1% of patients receiving 80 mg achieved MASH resolution without worsening fibrosis, compared with 9.7% on placebo (P<0.001). The 100 mg dose produced resolution in 29.9% of patients. For the fibrosis co-primary endpoint, 24.2% of patients on 80 mg achieved ≥1-stage improvement in fibrosis score without MASH worsening, versus 14.2% on placebo [1]. These are meaningful absolute risk differences by any standard clinical measure.

The Enrollment Gap for East Asian Patients

MAESTRO-NASH did not publish ethnicity-stratified subgroup analyses for East Asian patients. The trial was conducted predominantly at US and European sites [1]. Asian patients represented a small minority of total enrollment, and no subgroup forest plot breaking out East Asian response rates appears in the primary publication or supplementary data. This is a real gap. Regulatory agencies including the FDA have increasingly requested ethnicity-stratified data in NASH and MASH trials, but the MAESTRO-NASH dataset predates this requirement becoming routine.

What Subgroup Silence Means Clinically

Absence of East Asian subgroup data is not evidence of equivalent efficacy. Given the pharmacogenomic and phenotypic differences described above, it means clinicians are extrapolating from a population that may not represent their patient. The European Medicines Agency's reflection paper on extrapolation in drug development notes that ethnic factors can alter drug exposure enough to warrant bridging studies when the primary trial lacks adequate representation [7].

CYP2C19 and CYP2D6: The Pharmacogenomic Detail

CYP2C19 Poor Metabolizers

CYP2C19 poor metabolizers carry two non-functional alleles. In East Asian populations, CYP2C19*2 (c.681G>A splice variant) and CYP2C19*3 (c.636G>A stop-gain) together produce poor-metabolizer phenotypes in approximately 13-23% of individuals, depending on the specific East Asian subgroup [3]. Han Chinese populations show CYP2C19 poor-metabolizer rates near 18-23%, while Japanese populations show rates near 15-20% [3].

For resmetirom, CYP2C8 is the primary metabolic enzyme, but CYP2C19 contributes to secondary metabolic clearance. A poor metabolizer at CYP2C19 may show modestly elevated area-under-the-curve (AUC) for resmetirom. The resmetirom prescribing information states that strong CYP2C8 inhibitors increase resmetirom AUC by approximately 2.3-fold and require dose reduction [2]. CYP2C19 poor-metabolizer status produces a smaller but directionally similar effect.

CYP2D6 Ultrarapid Metabolizers

CYP2D6 contributes to resmetirom metabolism at higher substrate concentrations. East Asian populations show lower frequencies of CYP2D6 ultrarapid-metabolizer alleles (such as CYP2D6*2xN gene duplication) compared with Middle Eastern or North African populations, so this is less of a concern in East Asian patients than CYP2C19 [8]. The PharmGKB annotation for resmetirom lists CYP2C8 as the primary gene of interest, with CYP2C19 and CYP2D6 as secondary [4].

Practical Genotyping Considerations

Preemptive pharmacogenomic testing for CYP2C8 and CYP2C19 before initiating resmetirom is not currently mandated by the FDA label. The Clinical Pharmacogenomics Implementation Consortium (CPIC) has not yet published a resmetirom-specific guideline, given the drug's recent approval. Clinicians treating East Asian patients may choose to check CYP2C19 phenotype through commercial panels that return results in 5-10 business days, then apply clinical judgment about whether the 80 mg starting dose is appropriate. A CYP2C19 poor metabolizer starting at 80 mg rather than 100 mg may represent a reasonable conservative approach pending further data.

BMI-Based Dosing and East Asian Body Composition

Why Standard BMI Thresholds Underestimate Risk

The resmetirom dosing algorithm (80 mg for BMI <35 kg/m², 100 mg for BMI ≥35 kg/m²) was derived from pharmacokinetic and efficacy modeling in the MAESTRO trials, which enrolled predominantly Western patients [1]. East Asian individuals carry proportionally more visceral adipose tissue at lower BMI values [5]. A meta-analysis published in Diabetes Care (N=310,283) found that the BMI cutpoint for equivalent metabolic risk in East Asian adults is roughly 2-3 units lower than in European adults [9].

This creates a practical mismatch. An East Asian patient with BMI 28 kg/m² and biopsy-confirmed F3 fibrosis may have metabolic and hepatic disease severity equivalent to a European patient at BMI 31 kg/m², yet both receive 80 mg under current labeling. Whether 80 mg is sufficient in this context remains unknown because East Asian patients were not studied in adequate numbers in MAESTRO-NASH.

Waist Circumference as a Supplementary Metric

The WHO and the International Diabetes Federation both recommend using waist circumference thresholds specific to East Asian populations: ≥90 cm for men and ≥80 cm for women, compared with ≥102 cm and ≥88 cm in European reference populations [6]. Incorporating waist circumference into the clinical assessment of East Asian MASH patients on resmetirom may help identify those with more severe visceral adiposity who could benefit from closer monitoring or specialist referral for dose optimization.

Hepatic Outcomes and the MASH Fibrosis Spectrum in East Asian Populations

Epidemiology Differences

MASH (previously called NASH) affects an estimated 3-5% of the global adult population, but prevalence rates in East Asia have risen sharply. A 2023 systematic review in the Journal of Hepatology (N=8.5 million) estimated MASH prevalence at 3.7% in the general East Asian population, with higher rates in those with type 2 diabetes [10]. East Asian MASH patients present with advanced fibrosis at lower body weight, meaning the disease may be more aggressive per unit of adiposity.

Thyroid Hormone Receptor Beta Expression

Resmetirom's mechanism depends on THR-beta expression in hepatocytes. There is no published evidence that THR-beta hepatic expression levels differ by ethnicity, but this has not been systematically studied [2]. Mitochondrial dysfunction patterns and lipid metabolism enzyme activity can vary across ethnic groups due to both genetic and dietary factors, and these upstream processes feed into the hepatic lipid overload that resmetirom targets [11].

ALT and AST Response as Surrogate Markers

In MAESTRO-NASH, resmetirom produced significant reductions in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) at both doses [1]. ALT reduction correlated with histologic MASH resolution in the trial. East Asian patients often present with MASH at lower baseline ALT levels than Western patients, a phenomenon sometimes called "lean NASH" or "cryptogenic NASH in the lean." If East Asian patients start with lower baseline ALT, the absolute reduction achievable with resmetirom may be smaller in raw terms, even if the relative hepatic benefit is similar. No ethnicity-stratified ALT data from MAESTRO-NASH have been published to confirm or refute this hypothesis.

Drug Interactions Relevant to East Asian Patients

Statin Co-Administration

The resmetirom prescribing information includes warnings about increased statin exposure. Resmetirom inhibits OATP1B1 and OATP1B3 transporters, raising plasma concentrations of co-administered statins including rosuvastatin and atorvastatin [2]. Rosuvastatin is particularly relevant because East Asian patients show approximately 2-fold higher rosuvastatin plasma exposure compared with White patients at equivalent doses, a difference the FDA labels explicitly [12]. A Japanese patient on resmetirom plus rosuvastatin could face a compounded increase in statin exposure, raising the risk of statin-associated myopathy. The FDA label recommends limiting rosuvastatin to 20 mg daily when co-administered with resmetirom [2]. In East Asian patients, starting at rosuvastatin 10 mg daily when combining with resmetirom may be more appropriate pending direct pharmacokinetic data.

Proton Pump Inhibitors and CYP2C19

Many East Asian patients use proton pump inhibitors (PPIs) such as omeprazole or lansoprazole, which are strong CYP2C19 inhibitors. Because CYP2C19 contributes to resmetirom clearance, concurrent PPI use in a CYP2C19 poor metabolizer could produce additive increases in resmetirom exposure. This interaction has not been studied specifically in East Asian populations or in CYP2C19 stratified analyses.

What Clinicians Should Do Now

Patient Assessment Before Starting Resmetirom

Before initiating resmetirom in an East Asian patient, clinicians should confirm biopsy or non-invasive test evidence of F2-F3 fibrosis, check baseline ALT and AST, document all current medications with attention to CYP2C8 inhibitors and statins, review CYP2C19 phenotype if preemptive pharmacogenomic testing is available, and apply East Asian-specific BMI and waist circumference thresholds when assessing metabolic severity.

Monitoring During Treatment

The MAESTRO-NASH protocol assessed histology at 52 weeks [1]. For East Asian patients where the pharmacokinetic profile may differ, more frequent liver enzyme monitoring at weeks 4, 8, and 12 could help detect either inadequate response or elevated drug exposure earlier. The FDA label recommends checking LDL cholesterol at baseline and periodically, since resmetirom lowers LDL by approximately 13-16% through thyromimetic effects on hepatic lipid metabolism [2].

Dose Selection Considerations

The FDA-approved dose for BMI <35 kg/m² is 80 mg daily. For East Asian patients with BMI in the 23-27 kg/m² range who have confirmed advanced fibrosis, clinicians should document the rationale for dose selection carefully, acknowledging that the 80 mg dose may under-represent their actual disease severity relative to Western trial populations. Some clinicians may choose to discuss with their institutional pharmacogenomics service whether CYP2C19 genotyping changes the dose decision.

"The limited representation of East Asian patients in key MASH trials means that extrapolating efficacy data requires caution," according to a 2023 American Association for the Study of Liver Diseases (AASLD) position statement on diversity in hepatology clinical trials [13]. The statement called for mandatory ethnicity-stratified subgroup analyses in all future liver disease registration trials.

The FDA's Project Equity framework, launched in 2022, explicitly asks sponsors to enroll adequate numbers of underrepresented racial and ethnic groups and to submit disaggregated subgroup analyses [14]. Whether Madrigal Pharmaceuticals will conduct a dedicated East Asian pharmacokinetic bridging study for resmetirom remains to be seen.

Regulatory and Guideline Field for East Asian MASH

The Japan Pharmaceuticals and Medical Devices Agency (PMDA) has its own requirements for ethnicity bridging data, and Taiwan's FDA and South Korea's Ministry of Food and Drug Safety each impose similar standards for drugs approved elsewhere before local applications are submitted. Resmetirom's regulatory status in East Asian markets as of early 2025 is pending, and these agencies are likely to require either dedicated pharmacokinetic studies in East Asian populations or strong subgroup analyses from existing trial data before granting approval.

The AASLD practice guidance updated in 2023 defines the eligible population for pharmacologic MASH treatment as adults with F2-F3 fibrosis confirmed by biopsy or validated non-invasive tests, with appropriate attention to comorbidities [15]. This guidance does not yet include ethnicity-specific dosing recommendations for any approved MASH drug, reflecting the current gap in ethnicity-stratified trial data.